Quarterly report pursuant to Section 13 or 15(d)

Dispositions - Additional Information (Details)

v3.7.0.1
Dispositions - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Nov. 04, 2015
Feb. 28, 2017
Jun. 30, 2017
Jun. 30, 2017
Asset Purchase Agreement and Nanotherapeutics License Agreement [Member]        
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]        
Cash payments from Nanotherapeutics   $ 4,500,000    
Number of shares removed from obligation to issue of common stock   23,008    
Contingent upon achieving certain specified future operating objectives   $ 3,000,000    
Amount entitled to receive     $ 1,600,000 $ 1,600,000
Amount received from sale of discontinued operation     300,000 400,000
Remaining amount receivable in quarterly installments     $ 1,200,000 $ 1,200,000
Biodefense Business [Member]        
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]        
Sales of business, number of common stock shares eligible to receive 23,008      
Royalties receivable percentage on net sales 15.00%      
Biodefense Business [Member] | Maximum [Member]        
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]        
Cash payments from Nanotherapeutics $ 4,500,000